Annovis Bio, Inc.
ANVS NYSE· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.00
KIRA · Stoqly’s AI analyst, in plain words
- Annovis Bio, Inc. had $0.0M of revenue in fiscal 2025.
- Annovis Bio, Inc. lost $28.9M in fiscal 2025.
Market cap
$37.5M
P/E
—
Revenue
$0.0M
Net income
−$28.9M
Free cash flow
—
Operating margin
—
Annovis Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$28.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Annovis Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- Annovis Bio, Inc.
- CIK
- 0001477845
Annovis Bio, Inc. · ANVS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$14.5M | −$25.3M | −$56.2M | −$24.6M | −$28.9M |
| Diluted EPS | −$1.90 | −$3.10 | −$6.23 | −$2.31 | −$1.40 |
| Cash | |||||
| Cash from operations | −$9.1M | −$17.3M | −$40.0M | −$21.9M | −$25.6M |
| Share count change | 20.9% | 7.0% | 10.5% | 35.6% | 68.0% |
| Debt and strength | |||||
| Cash and short-term investments | $45.7M | $28.4M | $5.8M | $10.6M | $19.5M |
| Shareholders' equity | $44.5M | $28.3M | −$7.8M | $9.3M | $16.9M |
| Current ratio | 30.5x | 4.7x | 2.4x | — | — |
| Returns and quality | |||||
| Return on equity | −55.7% | −69.6% | −546.4% | −3,159.1% | −220.6% |
| Return on tangible equity | −32.6% | −89.4% | — | −264.2% | −171.2% |
| Piotroski F-score | 3 | 1 | 1 | — | — |
| Altman Z'' | 33.2 | −0.6 | −61.5 | — | — |
Insiders bought, 12 months
$4.3M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Annovis Bio, Inc. · ANVS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.00 a share, the company is worth $37.5M.
Source: SEC EDGAR XBRL filings (CIK 0001477845). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.